GlassScriptPhysician profile
Anne V Dall
NPI 1548266281
$6,474.80
in general payments reported to CMS, 2019-2025
19 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,419 · 2020: $197 · 2021: $706 · 2022: $153.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $2,978.94 | 2019-2020 | |
| Sunovion Pharmaceuticals INC. | $1,584.42 | 2019-2021 | |
| Otsuka America Pharmaceutical, INC. | $354.75 | 2019-2021 | |
| Abbvie INC. | $236.38 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $213.96 | 2019-2021 | |
| Lundbeck LLC | $204.49 | 2019-2021 | |
| Ironshore Pharmaceuticals INC. | $133.41 | 2019-2022 | |
| Alkermes, INC. | $111.64 | 2019-2022 | |
| Neurocrine Biosciences, INC. | $110.05 | 2019-2020 | |
| Jazz Pharmaceuticals INC. | $90.65 | 2019-2022 | |
| Vanda Pharmaceuticals INC. | $85.22 | 2019 | |
| Shire North American Group INC | $81.18 | 2019 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $77.06 | 2021 | |
| Janssen Pharmaceuticals, INC | $64.22 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $52.33 | 2021 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $38.91 | 2021 | |
| Eisai INC. | $24.39 | 2021 | |
| Noven Pharmaceuticals, INC. | $23.39 | 2021 | |
| Neuronetics, INC. | $9.41 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anne Dall listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.